$100 Million Acquisition, Giant Gene Sequencing Again
According to NBC News news, the gene sequencing giant Illumina announced on May 16 that it has acquired data analysis company EdicoGenome to accelerate the reading of next-generation sequencing data. The latter is NGS (high-throughput sequencing) data analysis. A leading provider of accelerated solutions.
Translation: Illumina for $ 100 million acquisition of Edico Genome, Edico Genome specializing in the data generated by genome sequencing.
Although the financial details of the transaction have not been disclosed, the Illumina spokesperson confirmed that the acquisition amounted to 100 million U.S. dollars.
In response, Susan Tousi, illumina's senior vice president of product development, said in a statement: 'Acquisition of EdicoGenome is a move toward achieving 'sampling and analysis of sequencing data to button-style standard A big step towards the vision of the process.'
And Pieter van Rooyen, President and CEO of Edico, added: "With the expansion of sequencing, reducing the cost and time of analysis is of great significance to the clinical application of sequencing."
It is known that, at present, the use of NGS is developing at an unprecedented speed, which brings about the need for technology that can quickly and accurately process large data.
The DRAGEN, a bioinformatic processor dedicated to the analysis of next-generation sequencing data developed by Edico Genome, can reduce genome-wide data analysis work from hours to minutes, while maintaining high accuracy and reducing costs. DRAGEN was selected by TheScientist Magazine. 'Top Ten Innovative Products of 2014'.
Obviously, this acquisition will help illumina to expand the NGS market. Illumina has also done so frequently.
On April 10, 2018, illumina and Loxo Oncology announced the establishment of a global strategic partnership that will jointly develop and promote Cancer Extensively analyzed multi-gene panels, resulting in a distributable NGS companion diagnosis (CDx) with multiple cancer indications.
Three days later, the company announced its cooperation with pharmaceutical giant Bristol-Myers Squibb, which will develop and conduct in vitro diagnostic (IVD) tests on Illumina's NGS technology to support Bristol-Myers Squibb's oncology product line.
In the Chinese market, Illumina has entered into a cooperation agreement with China's leading personal genome service company, WeGene (Shenzhen Early Know Technology Co., Ltd.), which will use the Illumina gene chip platform to establish a leading chip lab in Asia. Illumina To promote China's consumer testing market in the form of partners.
This time, DRAGEN, the bioinformatic processor for next-generation sequencing data, will also play a role in this cooperation project.
According to Illumina's revenue in the past three years, it is showing that the proportion of instrument sales has fallen, and that of consumable reagents has increased.
According to Illumina's annual report, there are four main sources of income: instrument sales, array genetic analysis products, reagent consumables, and other service revenues. equipment Sales has always been an important source of income for Illumina.
In 2017, Illumina's global revenue was 2.75 billion U.S. dollars, of which China accounted for about 10%.
The total sales revenue of the instrument was approximately US$515 million, which accounted for 19% of the total revenue. Compared with the sales revenue of instrument sales in 2015 and 2016, they accounted for 27% and 20% respectively, showing a year-on-year downward trend.
As a supporting product of the equipment, the revenue of consumables and reagents has increased.
In 2015 and 2016, the income of reagent supplies was 58% and 64%. In 2017, the total sales revenue of reagent consumables increased from 1.543 billion in 2016 to 1.753 billion, accounting for 64% of the total.
After acquiring data analysis company EdicoGenome to accelerate the reading of next-generation sequencing data, Illumina, which focuses on sequencing instruments and consumables in the Chinese market, will also speed up the layout.
